Cargando…

Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids

Antibiotic treatment is a standard therapy for Clostridioides difficile infection, but dysbiosis of the gut microbiota due to antibiotic exposure is also a major risk factor for the disease. Following an initial episode of C. difficile infection, a relentless cycle of recurrence can occur, where per...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qian, Xi, Yanagi, Karin, Kane, Anne V., Alden, Nicholas, Lei, Ming, Snydman, David R., Vickers, Richard J., Lee, Kyongbum, Thorpe, Cheleste M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Physiological Society 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500266/ https://www.ncbi.nlm.nih.gov/pubmed/32597706 http://dx.doi.org/10.1152/ajpgi.00046.2020

Ejemplares similares

2567. Effect of Broad vs. Narrow-Spectrum Clostridioides difficile Treatment on Human Stool Bile Acid Composition Over Time
por: Thorpe, Cheleste M, et al.
Publicado: (2019)

2578. Narrow-Spectrum Antibiotic Treatment of Clostridium difficile Infection Improves Preservation of Intestinal Metabolic Profile
por: Park, Seoyoung, et al.
Publicado: (2019)

Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin
por: Thorpe, Cheleste M., et al.
Publicado: (2018)

1774. Ridinilazole (RDZ) for Clostridium difficile infection (CDI): Correlation of In Vitro Spectrum of Activity with Human Gut Microbiome Profiles from a Phase 2 Clinical Trial
por: Vickers, Richard, et al.
Publicado: (2018)

Ridinilazole: a novel, narrow‐spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile
por: Collins, Deirdre A, et al.
Publicado: (2022)

A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020–2021
por: Snydman, D. R., et al.
Publicado: (2023)

Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile
por: Collins, Deirdre A, et al.
Publicado: (2020)

Ridinilazole: a novel antimicrobial for Clostridium difficile infection
por: Cho, Jonathan C., et al.
Publicado: (2019)

1052. Characterisation of the DNA binding properties of ridinilazole, a selective antibiotic currently in phase III trials for the treatment of Clostridioides difficile
por: Mason, Clive, et al.
Publicado: (2021)

Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection
por: Bassères, Eugénie, et al.
Publicado: (2016)

The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic
por: Mason, Clive S., et al.
Publicado: (2023)

1344. Ridinilazole (RDZ) for Clostridium difficile Infection (CDI): Impact of Diagnostic Method on Outcomes From a Phase 2 Clinical Trial
por: Vickers, Richard, et al.
Publicado: (2018)

1361. Pharmacokinetics and Safety of Ridinilazole (RDZ), a Potential New Therapy for Clostridium difficile Infection (CDI): From Animal Models to Patients
por: Duperchy, Esther, et al.
Publicado: (2018)

2387. Selecting Clostridium difficile Infection (CDI) Outcome Measures Relevant to Public Health Concerns: Experience From a Ridinilazole (RDZ) Phase 2 Trial
por: Vickers, Richard, et al.
Publicado: (2018)

668. Quality of Life Changes in Patients with Clostridium difficile Infection (CDI): A Randomized, Double-Blind Trial of Ridinilazole (RDZ) Compared with Vancomycin (VAN)
por: Paul, Sumita, et al.
Publicado: (2019)

Changes in microbiota composition, bile and fatty acid metabolism, in successful faecal microbiota transplantation for Clostridioides difficile infection
por: Brown, Jillian R.-M., et al.
Publicado: (2018)

1369. Combined Analysis of the In Vitro Activity of Ridinilazole (RDZ) Against More Than 500 Clostridium difficile (CD) Clinical Isolates and Impact of RDZ on Cell Morphology
por: Duperchy, Esther, et al.
Publicado: (2018)

Differential View on the Bile Acid Stress Response of Clostridioides difficile
por: Sievers, Susanne, et al.
Publicado: (2019)

Bile acid-independent protection against Clostridioides difficile infection
por: Aguirre, Andrea Martinez, et al.
Publicado: (2021)

The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection
por: Mullish, Benjamin H., et al.
Publicado: (2021)

Impact of Primary and Secondary Bile Acids on Clostridioides Difficile Infection
por: Łukawska, Agata, et al.
Publicado: (2022)

Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection
por: Mullish, Benjamin H, et al.
Publicado: (2019)

Gut microbiota and microbiota-based therapies for Clostridioides difficile infection
por: Chopra, Teena, et al.
Publicado: (2023)

Fecal Microbiota of Toxigenic Clostridioides difficile-Associated Diarrhea
por: Hernández, Marta, et al.
Publicado: (2019)

Fecal microbiota transplantation beyond Clostridioides difficile infections
por: Wortelboer, Koen, et al.
Publicado: (2019)

Intestinal Microbiota in Elderly Inpatients with Clostridioides difficile Infection
por: Vakili, Bahareh, et al.
Publicado: (2020)

Fecal Microbiota Transplantation beyond Clostridioides Difficile Infection
por: Moon, Chang Mo, et al.
Publicado: (2021)

54101 Characterizing Microbiota Features of Clostridioides difficile Infections
por: Tomkovich, Sarah, et al.
Publicado: (2021)

Microbial ecology between Clostridioides difficile and gut microbiota
por: KAMIYA, Shigeru
Publicado: (2023)

Bile salt hydrolases shape the bile acid landscape and restrict Clostridioides difficile growth in the murine gut
por: Foley, Matthew H., et al.
Publicado: (2023)

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study
por: Vickers, Richard J, et al.
Publicado: (2017)

Destination and Specific Impact of Different Bile Acids in the Intestinal Pathogen Clostridioides difficile
por: Metzendorf, Nicole G., et al.
Publicado: (2022)

Application of Microbiome Management in Therapy for Clostridioides difficile Infections: From Fecal Microbiota Transplantation to Probiotics to Microbiota-Preserving Antimicrobial Agents
por: Chiu, Chun-Wei, et al.
Publicado: (2021)

381. Antibiotic Spectrum Index and Risk of Clostridioides difficile Infection
por: Ray, Michael J, et al.
Publicado: (2022)

Human Fecal Bile Acid Analysis after Investigational Microbiota-Based Live Biotherapeutic Delivery for Recurrent Clostridioides difficile Infection
por: Papazyan, Romeo, et al.
Publicado: (2023)

Gut microbiota features associated with Clostridioides difficile colonization in puppies
por: Berry, Alexander S. F., et al.
Publicado: (2019)

Insights into the Role of Human Gut Microbiota in Clostridioides difficile Infection
por: Kachrimanidou, Melina, et al.
Publicado: (2020)

Microbiota-based markers predictive of development of Clostridioides difficile infection
por: Berkell, Matilda, et al.
Publicado: (2021)

Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls
por: Sandhu, Avnish, et al.
Publicado: (2021)

Gut Microbiota Composition Associated with Clostridioides difficile Colonization and Infection
por: Martinez, Elisa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u137kd3g1glvs5p6dfjc64eff9